Investigational drug · Phase 2
TL938
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Colorectal Cancer Metastatic, Advanced Colorectal Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "TL938"
First trial start
2025
May 13, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TL938", any sponsor or status.
Conditions studied
As listed on its trial records.
- Colorectal Cancer Metastatic
- Advanced Colorectal Cancer
Approved drugs for the same conditions: Colorectal cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "TL938" as an intervention, largest first.
- TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal CancerPivotal-lookingRecruiting
Teligene USIndustry
NCT06589830 · 110 participants (planned) · Start May 13, 2025 · Primary completion Dec 2028
Drug: TL938 Capsules; Trastuzumab · For: Colorectal Cancer Metastatic; Advanced Colorectal Cancer
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Colorectal Cancer Metastatic
- TunlametinibPhase 32 trials
Shanghai Kechow Pharma, Inc. · Colorectal Cancer Metastatic, Melanoma
- EB-DUO-CAR-NK-CEAGCCPhase 22 trials
Beijing Biotech · Colorectal Cancer Metastatic, Adenocarcinoma of Colon, Colorectal Cancer
- HDM2017Phase 22 trials
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · CRC, Colorectal Cancer, Colorectal Cancer Metastatic
- XNW27011ASP546CPhase 22 trials
Astellas · Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma Metastatic
- DKN-01LY2812176Phase 21 trial
Leap Therapeutics, Inc. · Colorectal Cancer, Colorectal Adenocarcinoma, Colo-rectal Cancer
- ImofinostatABT-301, MPT0E028Phase 21 trial
Anbogen Therapeutics, Inc. · Colorectal Cancer (Diagnosis), Colorectal Cancer Metastatic, Colorectal Cancer (CRC)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.